195 related articles for article (PubMed ID: 20350915)
1. Treatment of thyroid-associated orbitopathy with rituximab--a novel therapy for an old disease: case report and literature review.
Madaschi S; Rossini A; Formenti I; Lampasona V; Marzoli SB; Cammarata G; Politi LS; Martinelli V; Bazzigaluppi E; Scavini M; Bosi E; Lanzi R
Endocr Pract; 2010; 16(4):677-85. PubMed ID: 20350915
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.
Salvi M; Vannucchi G; Campi I; Currò N; Dazzi D; Simonetta S; Bonara P; Rossi S; Sina C; Guastella C; Ratiglia R; Beck-Peccoz P
Eur J Endocrinol; 2007 Jan; 156(1):33-40. PubMed ID: 17218723
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment with rituximab in a patient with stiff-person syndrome complicated by dysthyroid ophthalmopathy.
Katoh N; Matsuda M; Ishii W; Morita H; Ikeda S
Intern Med; 2010; 49(3):237-41. PubMed ID: 20118602
[TBL] [Abstract][Full Text] [Related]
4. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy.
Khanna D; Chong KK; Afifiyan NF; Hwang CJ; Lee DK; Garneau HC; Goldberg RA; Darwin CH; Smith TJ; Douglas RS
Ophthalmology; 2010 Jan; 117(1):133-139.e2. PubMed ID: 19818507
[TBL] [Abstract][Full Text] [Related]
5. Stiff-person syndrome treated with rituximab.
Lobo ME; Araújo ML; Tomaz CA; Allam N
BMJ Case Rep; 2010 Dec; 2010():. PubMed ID: 22802263
[TBL] [Abstract][Full Text] [Related]
6. Stiff person syndrome (SPS) complicated by respiratory failure: successful treatment with rituximab.
Qureshi A; Hennessy M
J Neurol; 2012 Jan; 259(1):180-1. PubMed ID: 21647727
[No Abstract] [Full Text] [Related]
7. Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy.
Bonara P; Vannucchi G; Campi I; Rossi S; Cantoni F; Frugoni C; Sbrozzi F; Guastella C; Avignone S; Beck-Peccoz P; Salvi M
Clin Rev Allergy Immunol; 2008 Feb; 34(1):118-23. PubMed ID: 18270865
[TBL] [Abstract][Full Text] [Related]
8. Potential utility of rituximab for Graves' orbitopathy.
Salvi M; Vannucchi G; Beck-Peccoz P
J Clin Endocrinol Metab; 2013 Nov; 98(11):4291-9. PubMed ID: 24009135
[TBL] [Abstract][Full Text] [Related]
9. Enduring remission of active and sight-threatening Graves' orbitopathy with rituximab: report of two cases.
Adamidou F; Anagnostis P; Boboridis K; Manani C; Georgiou T; Veneti S; Kita M
Endocr J; 2018 Sep; 65(9):963-967. PubMed ID: 29937466
[TBL] [Abstract][Full Text] [Related]
10. A Case of Stiff Person Syndrome: Immunomodulatory Effect of Benzodiazepines: Successful Rituximab and Tizanidine Therapy.
Zdziarski P
Medicine (Baltimore); 2015 Jun; 94(23):e954. PubMed ID: 26061327
[TBL] [Abstract][Full Text] [Related]
11. The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves' orbitopathy.
Mitchell AL; Gan EH; Morris M; Johnson K; Neoh C; Dickinson AJ; Perros P; Pearce SH
Clin Endocrinol (Oxf); 2013 Sep; 79(3):437-42. PubMed ID: 23320840
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression.
Salvi M; Vannucchi G; Campi I; Rossi S; Bonara P; Sbrozzi F; Guastella C; Avignone S; Pirola G; Ratiglia R; Beck-Peccoz P
Eur J Endocrinol; 2006 Apr; 154(4):511-7. PubMed ID: 16556712
[TBL] [Abstract][Full Text] [Related]
13. Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions.
Vannucchi G; Campi I; Bonomi M; Covelli D; Dazzi D; Currò N; Simonetta S; Bonara P; Persani L; Guastella C; Wall J; Beck-Peccoz P; Salvi M
Clin Exp Immunol; 2010 Sep; 161(3):436-43. PubMed ID: 20529087
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Rituximab for the Treatment of Graves' Orbitopathy: A Meta-analysis of Randomized Controlled Trials.
Shen WC; Lee CH; Loh EW; Hsieh AT; Chen L; Tam KW
Pharmacotherapy; 2018 May; 38(5):503-510. PubMed ID: 29601105
[TBL] [Abstract][Full Text] [Related]
15. Rituximab for thyroid eye disease.
Oh SR; Priel A; Levi L; Granet DB; Korn BS; Kikkawa DO
Ophthalmology; 2011 Apr; 118(4):792; author reply 792-3. PubMed ID: 21459230
[No Abstract] [Full Text] [Related]
16. Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab.
Hegedüs L; Smith TJ; Douglas RS; Nielsen CH
Clin Endocrinol (Oxf); 2011 Jan; 74(1):1-8. PubMed ID: 20455896
[TBL] [Abstract][Full Text] [Related]
17. New immunomodulators in the treatment of Graves' ophthalmopathy.
Salvi M; Vannucchi G; Campi I; Currò N; Beck-Peccoz P
Ann Endocrinol (Paris); 2008 Apr; 69(2):153-6. PubMed ID: 18417090
[TBL] [Abstract][Full Text] [Related]
18. B-cell targeted therapy with rituximab for thyroid eye disease: closer to the clinic.
Shen S; Chan A; Sfikakis PP; Hsiu Ling AL; Detorakis ET; Boboridis KG; Mavrikakis I
Surv Ophthalmol; 2013; 58(3):252-65. PubMed ID: 23253433
[TBL] [Abstract][Full Text] [Related]
19. [Novel treatment opportunities in Graves' orbitopathy].
Erdei A; Gazdag A; Bodor M; Berta E; Katkó M; Ujhelyi B; Steiber Z; Győry F; Urbancsek H; Barna S; Galuska L; Nagy VE
Orv Hetil; 2014 Aug; 155(33):1295-300. PubMed ID: 25109914
[TBL] [Abstract][Full Text] [Related]
20. Stiff-person syndrome: persistent elevation of glutamic acid decarboxylase antibodies despite successful treatment with rituximab.
Bacorro EA; Tehrani R
J Clin Rheumatol; 2010 Aug; 16(5):237-9. PubMed ID: 20577094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
